ArticleCureus2025
Epstein-Barr Virus-Positive Plasmablastic Lymphoma Arising in the Anal Canal of an Immunocompetent Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes a 57-year-old immunocompetent male diagnosed with Epstein-Barr virus (EBV)-positive plasmablastic lymphoma (PBL), a rare and aggressive subtype of diffuse large B-cell lymphoma (DLBCL), presenting in the anal canal. PBL is most commonly seen in immunocompromised patients, particularly those with a human immunodeficiency virus (HIV) infection; its presence in immunocompetent individuals is exceedingly rare. The patient presented with persistent anal pain, prompting a comprehensive diagnostic workup. Histopathological and immunohistochemical analysis confirmed PBL, with a high proliferation index and EBV-encoded RNA (EBER) positivity. The patient initially responded to dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) chemotherapy, with a reduction in mass size and metabolic activity. However, the disease relapsed, requiring further treatment with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy, followed by consolidation with autologous stem cell transplantation (ASCT), after which the patient remained in remission for six months. This report not only discusses the clinical and pathological findings but also explores the interplay between EBV and the immune system in tumor development. The case underscores the need for heightened clinical suspicion and the future potential for immunotherapeutic and EBV-targeted therapies for patients with EBV-positive PBL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.